Pathogenic mutations in LRRK2 account for 4-5% of familial and 1-2% of sporadic Parkinson’s disease. 1,2 BIIB122 (DNL151) is a selective, central nervous system-penetrant small molecule inhibitor of ...
Blarcamesine’s safety profile indicates not requiring routine MRI monitoring, and the advantage of blarcamesine is that it is a small oral molecule that exerts clinical benefits on cognition and ...